| Manivanh, Susan |
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention |
|
|
| Terminated | 2/3 | 538 | US | BHV-3500 (zavegepant), Placebo | Pfizer | Migraine | 03/24 | 03/24 | | |
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
|
|
| Active, not recruiting | 2 | 350 | US | LB-102 | LB Pharmaceuticals Inc. | Schizophrenia | 10/24 | 01/25 | | |
| Semeniuk, Charmaine |
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
|
|
| Active, not recruiting | 2 | 350 | US | LB-102 | LB Pharmaceuticals Inc. | Schizophrenia | 10/24 | 01/25 | | |
NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I |
|
|
| Active, not recruiting | N/A | 300 | Canada, US, RoW | ERG assessment (RSPA) | diaMentis Inc. | Schizophrenia, Bipolar I Disorder | 12/24 | 12/24 | | |
| Bari, Mohammed |
NCT05628103: A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication |
|
|
| Completed | 3 | 101 | US | SEP-363856 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 04/24 | 04/24 | | |
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia |
|
|
| Terminated | 3 | 463 | Europe, US, RoW | SEP-363856 | Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc. | Schizophrenia | 11/23 | 11/23 | | |
| Bari, Mohammad |
NCT05546229: Assessment of Methadone and Buprenorphine in Interstitial Fluid |
|
|
| Completed | N/A | 11 | US | Microneedle based interstitial fluid collection | Cari Health Inc., National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) | Opioid Use Disorder | 10/22 | 10/22 | | |
NCT05981573: Assessment of Methadone Dose Taken Using Electrochemistry |
|
|
| Enrolling by invitation | N/A | 30 | US | ISF extraction device 1, Samplimy, Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, dose taken peak-trough test, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, In vivo Differential Pulse Voltammetery ( DPV ), Measurement of Methadone in ISF before and after taking prescribed dose, Comparing in vitro and in vivo approaches to determining a dose taken, ISF Extraction Device 2, Ascilion | Cari Health Inc., Samplimy Medical AB | Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity | 03/25 | 04/25 | | |
NCT05998876: Assessing Dose Taken in Opioid Use Disordered Patients With an Electrochemical Sensor |
|
|
| Not yet recruiting | N/A | 45 | NA | Remote Medication Monitor (RMM) - Prototype, RMM, Daily Methadone Dose, Dose Taken | Cari Health Inc. | Adherence, Medication, Opioid Use Disorder | 05/24 | 06/24 | | |
| Coordinator |
NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) |
|
|
| Recruiting | 4 | 12 | US | Asceniv™ | ADMA Biologics, Inc. | Primary Immune Deficiency | 03/23 | 06/23 | | |
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies |
|
|
| Recruiting | 3 | 143 | Europe, US | Intervention/Treatment | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/25 | 03/26 | | |
| Recruiting | 3 | 402 | US | Brilaroxazine, RP5063, Placebo | Reviva Pharmaceuticals | Schizophrenia | 10/24 | 10/24 | | |
STRIVE, NCT06384547: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 212 | US | VRDN-001 10 mg/kg, VRDN-001 3 mg/kg | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 05/25 | 01/26 | | |
REVEAL-1, NCT06625411: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 84 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 03/26 | 11/26 | | |
REVEAL-2, NCT06625398: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Recruiting | 3 | 126 | US | VRDN-003, Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 04/26 | 12/26 | | |
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 3 | 188 | Europe, US, RoW | Veligrotug (VRDN-001), Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 12/24 | 09/25 | | |
NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease |
|
|
| Recruiting | 2 | 100 | US | Carmustine 7.7Mg Wafer, GLIADEL | University of Nebraska, Arbor Pharmaceuticals, Inc. | Brain Tumor - Metastatic | 12/25 | 12/26 | | |
NCT06107686: A Study of YL202 in Selected Patients with Advanced Solid Tumors |
|
|
| Recruiting | 2 | 200 | RoW | YL202 should be intravenously infused | MediLink Therapeutics (Suzhou) Co., Ltd. | NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors | 11/26 | 11/28 | | |
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 640 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumor | 10/26 | 10/27 | | |
NCT06186596: Self-Administered Intralesional Injections for Acne |
|
|
| Recruiting | N/A | 150 | US | Triamcinolone delivered via injection assistance device | ACOM Labs | Acne Vulgaris | 01/24 | 01/24 | | |
NCT05879198: Train Your Brain: A Pilot Project to Improve Memory and Decision Making |
|
|
| Completed | N/A | 24 | US | Computer-based Intervention | Henry Ford Health System, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) | Behavior, Health | 09/23 | 09/23 | | |
PRIMA-102, NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD |
|
|
| Recruiting | N/A | 830 | US | | Aqtual, Inc. | Rheumatoid Arthritis | 03/25 | 09/25 | | |
NCT04642898: Increasing Treatment Efficacy Using SMART Methods for Personalizing Care |
|
|
| Completed | N/A | 66 | US | Standard UP Treatment, Capitalization UP Treatment, Compensation UP Treatment | Shannon E. Sauer-Zavala, National Institute of Mental Health (NIMH) | Anxiety Disorders, Post Traumatic Stress Disorder, Obsessive-Compulsive Disorder | 06/24 | 06/24 | | |
NCT03594994: Metabolic Effects of Sleep Extension in People With Obesity |
|
|
| Completed | N/A | 40 | US | Sleep extension | Washington University School of Medicine | Insulin Resistance, Obesity | 07/24 | 07/24 | | |
NCT06242704: Train Your Brain 2.0 - Improving Memory and Decision Making Among Youth |
|
|
| Recruiting | N/A | 72 | US | Working Memory Training, Working Memory | Henry Ford Health System | Behavior, Health | 08/26 | 08/26 | | |
NCT04587518: Five Factor Model Treatment for Borderline Personality Disorder |
|
|
| Completed | N/A | 100 | US | Personality-Based Cognitive Behavioral Therapy | Shannon E. Sauer-Zavala | Borderline Personality Disorder | 05/24 | 05/24 | | |
| Active, not recruiting | N/A | 1017 | US | Impella 5.5 | Abiomed Inc. | Cardiogenic Shock, Acute Decompensated Heart Failure | 12/24 | 12/24 | | |
ELEVATE-HF, NCT06592508: Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure |
|
|
| Recruiting | N/A | 180 | US | Remote Virtual Cardiology Program | Duke University, Ventricle Health | Heart Failure; With Decompensation | 08/26 | 08/26 | | |
NCT03701828: Liver Health and Metabolic Function in People With Obesity |
|
|
| Enrolling by invitation | N/A | 30 | US | Weight loss surgery, Sleeve gastrectomy, Roux-en-Y, biliopancreatic diversion | Washington University School of Medicine | Non-Alcoholic Fatty Liver Disease | 11/24 | 03/25 | | |
| Recruiting | N/A | 87 | US | Telemedicine | University of Pennsylvania | Psoriatic Arthritis | 02/25 | 02/25 | | |
| Recruiting | N/A | 200 | Europe | Modified prolonged exposure, Brief intervention, cognitive behavioral therapy | St. Olavs Hospital, Norwegian University of Science and Technology, The Research Council of Norway, Norwegian Women's Public Health Association (Norske Kvinners Sanitetsforening), National Centre for Emergency Primary Health Care, NORCE, UiT The Arctic University of Norway | Post Traumatic Stress Disorder, Rape Sexual Assault, Sexual Dysfunctions, Psychological, Pelvic Floor Myalgia, Pelvic Pain Syndrome, Depression, Anxiety, Sleep Disturbance, Activity, Motor, Cortisol Deficiency | 05/25 | 12/27 | | |
| Recruiting | N/A | 506 | US | CHOICES, eBook | University of Florida, National Human Genome Research Institute (NHGRI) | Sickle Cell Disease, Sickle Cell Trait | 06/25 | 06/25 | | |
| Active, not recruiting | N/A | 220 | US | EXTEND Plus, EXTEND | Duke University, National Institute of Nursing Research (NINR) | Diabetes Mellitus, Type 2, Hypertension | 10/25 | 10/25 | | |
| Weise, Corey |
| Recruiting | 2/3 | 256 | US | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Bipolar Disorder | 03/25 | 04/25 | | |
| Dolnak, Douglas |
| No trials found |
| Watts, Joshua |
| No trials found |
| Price, Eric |
| No trials found |
| Woodaman, Ryan |
| No trials found |
